Last updated: 21 July 2019 at 9:58pm EST

Trevor Phillips Net Worth




The estimated Net Worth of Trevor Phillips is at least $272 Thousand dollars as of 25 June 2007. Trevor Phillips owns over 1,389 units of Cortexyme Inc stock worth over $74,533 and over the last 20 years Trevor sold CRTX stock worth over $197,095.

Trevor Phillips CRTX stock SEC Form 4 insiders trading

Trevor has made over 9 trades of the Cortexyme Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Trevor exercised 1,389 units of CRTX stock worth $528 on 25 June 2007.

The largest trade Trevor's ever made was selling 14,500 units of Cortexyme Inc stock on 8 August 2006 worth over $58,145. On average, Trevor trades about 2,596 units every 36 days since 2004. As of 25 June 2007 Trevor still owns at least 38,222 units of Cortexyme Inc stock.

You can see the complete history of Trevor Phillips stock trades at the bottom of the page.



What's Trevor Phillips's mailing address?

Trevor's mailing address filed with the SEC is C/O CRITICAL THERAPEUTICS, INC., 60 WESTVIEW STREET, LEXINGTON, MA, 02421.

Insiders trading at Cortexyme Inc

Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.



What does Cortexyme Inc do?

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.



What does Cortexyme Inc's logo look like?

Cortexyme Inc logo

Complete history of Trevor Phillips stock trades at Cortexyme Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
25 Jun 2007 Trevor Phillips
COO, VP of Operations, and Sec.
Option 1,389 $0.38 $528
25 Jun 2007
38,222
8 Aug 2006 Trevor Phillips
COO, VP of Operations, and Sec.
Sale 14,500 $4.01 $58,145
8 Aug 2006
1,833
6 Mar 2006 Trevor Phillips
COO, VP of Operations, and Sec.
Option 5,000 $1.05 $5,250
6 Mar 2006
8,333
1 Feb 2006 Trevor Phillips
COO, VP of Operations, and Sec.
Option 2,500 $1.05 $2,625
1 Feb 2006
5,833
3 Jan 2006 Trevor Phillips
COO, VP of Operations, and Sec.
Option 3,333 $0.38 $1,267
3 Jan 2006
5,277
2 Dec 2005 Trevor Phillips
COO, VP of Operations, and Sec.
Sale 5,000 $6.27 $31,350
2 Dec 2005
1,944
2 Nov 2005 Trevor Phillips
COO, VP of Operations, and Sec.
Sale 5,000 $6.57 $32,850
2 Nov 2005
6,944
3 Oct 2005 Trevor Phillips
COO, VP of Operations, and Sec.
Sale 5,000 $9.05 $45,250
3 Oct 2005
11,944
19 Sep 2005 Trevor Phillips
COO, VP of Operations, and Sec.
Sale 5,000 $5.90 $29,500
19 Sep 2005
16,944


Cortexyme Inc executives and stock owners

Cortexyme Inc executives and other stock owners filed with the SEC include: